CDC20 and prostate cancer: In addition, multiple studies have indicated that CDC20 is overexpressed significantly along with poor prognosis in astrocytoma,[29] NSCLC,[13,30] HCC,[14] and prostate cancer.[18] Aberrant expression of the GTF2E2/CDC20 signaling pathway is associated with glioblastoma pathogenesis and poor prognosis.[31] Moreover, the expression of CDC20 was associated with the clinicopathological parameters of the tumors mentioned above.